PPCB (Propanc Biopharma) ROE % Adjusted to Book Value: -951.54% (As of Mar. 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.48
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma ROE % Adjusted to Book Value?

Propanc Biopharma PPCB +1.36% 29 ROE % Adjusted to Book Value is -951.54% as of Mar. 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Propanc Biopharma's ROE % for the quarter that ended in Mar. 2026 was -228.37%. Propanc Biopharma's PB Ratio for the quarter that ended in Mar. 2026 was 0.24. Propanc Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -951.54%.

Propanc Biopharma ROE % Adjusted to Book Value Related Terms

Propanc Biopharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma ROE % Adjusted to Book Value Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -336.32

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -879.43 -29.42 -90.08 -138.84 -951.54

PPCB vs ENSC, ACUT, LSBCF: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Propanc Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Propanc Biopharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's ROE % Adjusted to Book Value falls into.


PPCB
29GF Score
Propanc Biopharma Inc PPCB
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma ROE % Adjusted to Book Value Calculation

Propanc Biopharma's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1,163.68% / 3.46
=-336.32%

Propanc Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-228.37% / 0.24
=-951.54%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -951.54% mean?
Propanc Biopharma (PPCB) has a ROE % Adjusted to Book Value of -951.54% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Propanc Biopharma and its competitors.
Is Propanc Biopharma's ROE % Adjusted to Book Value too high?
Propanc Biopharma's current ROE % Adjusted to Book Value is -951.54%. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's ROE % Adjusted to Book Value compare to ENSC and ACUT?
Propanc Biopharma's ROE % Adjusted to Book Value of -951.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Propanc Biopharma and its competitors. Propanc Biopharma's current ROE % Adjusted to Book Value is -951.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current ROE % Adjusted to Book Value of -951.54%. The current ROE % Adjusted to Book Value is -951.54%. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current ROE % Adjusted to Book Value is -951.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price